Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Nov
03
Today In Oncology
Novel Strategy May Improve Outcomes in Patients With Treatment Resistant DLBCL
CAR T Cell Therapy May Be Effective but Unaffordable as Second Line Therapy for Patients With DLBCL
Second-Line Lisocabtagene Maraleucel May Be More Cost-Effective Than Standard-Care DLBCL Therapy
Combination Targeted Therapy Produces Durable Responses in Patients With Relapsed DLBCL
Shortening FDA Mandated CAR T Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo